Compound Detail
CHEMBL1201191
LEVOCETIRIZINE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL1201191 |
| Name | LEVOCETIRIZINE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | ZKLPARSLTMPFCP-OAQYLSRUSA-N |
| Therapeutic | ✓ Yes |
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
14
Publications
9
Known Names
12
Indications
Molecular Properties
388.9
MW (Da)
3.15
ALogP
4
HBA
1
HBD
53.0
PSA (Ų)
0.70
QED
0
Ro5 Violations
8
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2007 |
| Availability | OTC |
| Chirality | Single Enantiomer |
Indications
Hypersensitivity Asthma Dermatitis Eczema Rhinitis Rhinitis, Allergic, Perennial Rhinitis, Allergic, Seasonal Rhinitis, Allergic, Seasonal Rhinitis, Vasomotor Urticaria Colorectal Neoplasms Diabetic Nephropathies
ATC Classification
R06AE09
levocetirizine
Level 1: RESPIRATORY SYSTEM
Level 2: ANTIHISTAMINES FOR SYSTEMIC USE
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 25494650 | 10.1021/jm501535r | Molecular identity unknown | 2 |
| 31514017 | 10.1016/j.ejmech.2019.111643 | Sus scrofa | 2 |
| - | 10.6019/CHEMBL4808148 | Histone deacetylase 6 | 2 |
| 25494650 | 10.1021/jm501535r | ADMET | 1 |
| 25494650 | 10.1021/jm501535r | Nucleic Acid | 1 |
| - | 10.1101/2020.04.21.054387 | SARS-CoV-2 | 1 |
| 31514017 | 10.1016/j.ejmech.2019.111643 | ADMET | 1 |
| - | 10.6019/CHEMBL4513141 | Candida albicans | 1 |
| - | 10.6019/CHEMBL4513141 | Cryptococcus neoformans | 1 |
| - | 10.6019/CHEMBL4513141 | Escherichia coli | 1 |
| - | 10.6019/CHEMBL4513141 | Klebsiella pneumoniae | 1 |
| - | 10.6019/CHEMBL4513141 | Pseudomonas aeruginosa | 1 |
| - | 10.6019/CHEMBL4513141 | Acinetobacter baumannii | 1 |
| - | 10.6019/CHEMBL4513141 | Staphylococcus aureus | 1 |
Data from ChEMBL 36 via Core Engine